Literature DB >> 28986196

Effect of composition of simulated intestinal media on the solubility of poorly soluble compounds investigated by design of experiments.

Cecilie Maria Madsen1, Kung-I Feng2, Andrew Leithead2, Nicole Canfield3, Søren Astrup Jørgensen1, Anette Müllertz4, Thomas Rades1.   

Abstract

The composition of the human intestinal fluids varies both intra- and inter-individually. This will influence the solubility of orally administered drug compounds, and hence, the absorption and efficacy of compounds displaying solubility limited absorption. The purpose of this study was to assess the influence of simulated intestinal fluid (SIF) composition on the solubility of poorly soluble compounds. Using a Design of Experiments (DoE) approach, a set of 24 SIF was defined within the known compositions of human fasted state intestinal fluid. The SIF were composed of phospholipid, bile salt, and different pH, buffer capacities and osmolarities. On a small scale semi-robotic system, the solubility of 6 compounds (aprepitant, carvedilol, felodipine, fenofibrate, probucol, and zafirlukast) was determined in the 24 SIF. Compound specific models, describing key factors influencing the solubility of each compound, were identified. Although all models were different, the level of phospholipid and bile salt, the pH, and the interactions between these, had the biggest influences on solubility overall. Thus, a reduction of the DoE from five to three factors was possible (11-13 media), making DoE solubility studies feasible compared to single SIF solubility studies. Applying this DoE approach will lead to a better understanding of the impact of intestinal fluid composition on the solubility of a given drug compound.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aprepitant (PubChem CID: 6918365); Carvedilol (PubChem CID: 2585); Design of experiments; Felodipine (PubChem CID: 3333); Fenofibrate (PubChem CID: 3339); Poorly soluble compounds; Preformulation; Probucol (PubChem CID: 4912); Simulated intestinal fluid; Solubility; Zafirlukast (PubChem CID: 5717)

Mesh:

Substances:

Year:  2017        PMID: 28986196     DOI: 10.1016/j.ejps.2017.10.003

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Synthesis and characterization of a new cyclodextrin derivative with improved properties to design oral dosage forms.

Authors:  Agustina García; Josefina Priotti; Ana Victoria Codina; María Delia Vasconi; Ariel D Quiroga; Lucila I Hinrichsen; Dario Leonardi; María Celina Lamas
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 2.  Computational prediction of drug solubility in water-based systems: Qualitative and quantitative approaches used in the current drug discovery and development setting.

Authors:  Christel A S Bergström; Per Larsson
Journal:  Int J Pharm       Date:  2018-02-06       Impact factor: 5.875

3.  Topography of Simulated Intestinal Equilibrium Solubility.

Authors:  Claire Dunn; Jeremy Perrier; Ibrahim Khadra; Clive G Wilson; Gavin W Halbert
Journal:  Mol Pharm       Date:  2019-04-16       Impact factor: 4.939

4.  Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems.

Authors:  Qamar Abuhassan; Ibrahim Khadra; Kate Pyper; Patrick Augustijns; Joachim Brouwers; Gavin W Halbert
Journal:  Eur J Pharm Biopharm       Date:  2021-12-16       Impact factor: 5.571

5.  Small scale in vitro method to determine a bioequivalent equilibrium solubility range for fasted human intestinal fluid.

Authors:  Qamar Abuhassan; Ibrahim Khadra; Kate Pyper; Gavin W Halbert
Journal:  Eur J Pharm Biopharm       Date:  2021-08-20       Impact factor: 5.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.